2025
Gross tumor volume confidence maps prediction for soft tissue sarcomas from multi-modality medical images using a diffusion model
Dong Y, Marin T, Zhuo Y, Najem E, Moteabbed M, Xing F, Beddok A, Lahoud R, Rozenblum L, Ding Z, Liu X, Grogg K, Woo J, Chen Y, Lim R, Ma C, Fakhri G. Gross tumor volume confidence maps prediction for soft tissue sarcomas from multi-modality medical images using a diffusion model. Physics And Imaging In Radiation Oncology 2025, 33: 100734. PMID: 40123775, PMCID: PMC11926426, DOI: 10.1016/j.phro.2025.100734.Peer-Reviewed Original ResearchGross tumor volumeSoft tissue sarcomasTissue sarcomasGross tumor volume delineationManual GTV delineationsMagnetic resonance imagingComputed tomographyFluorodeoxyglucose positron emission tomographyGTV delineationT1-weighted magnetic resonance imagingSingle-modePositron emission tomographyMulti-modal medical imagesTumor volumeIntra-reader variabilityFDG-PETTreatment planningSarcomaEmission tomographyImaging modalitiesResonance imagingDiffusion modelDice indexReader variabilityPatientsDermatofibrosarcoma Protuberans, Version 1.2025, NCCN Clinical Practice Guidelines In Oncology.
Bordeaux J, Blitzblau R, Aasi S, Alam M, Amini A, Bibee K, Bolotin D, Chen P, Contreras C, DiMaio D, Donigan J, Farma J, Ghosh K, Harms K, LeBoeuf N, Lukens J, Manber S, Mark L, Medina T, Nehal K, Nghiem P, Olino K, Paragh G, Park S, Patel T, Rich J, Shaha A, Sharma B, Sokumbi Y, Srivastava D, Thomas V, Tomblinson C, Venkat P, Xu Y, Yu S, Yusuf M, McCullough B, Espinosa S. Dermatofibrosarcoma Protuberans, Version 1.2025, NCCN Clinical Practice Guidelines In Oncology. Journal Of The National Comprehensive Cancer Network 2025, 23 PMID: 39819674, DOI: 10.6004/jnccn.2025.0001.Peer-Reviewed Original ResearchConceptsNCCN Clinical Practice GuidelinesDermatofibrosarcoma protuberansClinical practice guidelinesNegative marginsFibrosarcomatous dermatofibrosarcoma protuberansRate of recurrenceSoft tissue sarcomasRecommended treatment optionPractice guidelinesCutaneous soft tissue sarcomasLocal recurrenceRadiation therapySurgical excisionAggressive variantSystemic treatmentInitial treatmentTissue sarcomasTreatment optionsLocal infiltrationIncreased riskRecurrenceMetastasisProtuberansMultidisciplinary teamNCCN
2024
CHAPTER-GIST-101: A phase I study of pimitespib combined with imatinib in patients with imatinib-refractory gastrointestinal stromal tumor.
Hirano H, Naito Y, Sundar R, Komatsu Y, Kurokawa Y, Li J, Ozaka M, Iwatsuki M, Chen J, Yen C, Zalcberg J, Roy A, Chen L, Nishida T, Doi T. CHAPTER-GIST-101: A phase I study of pimitespib combined with imatinib in patients with imatinib-refractory gastrointestinal stromal tumor. Journal Of Clinical Oncology 2024, 42: tps97-tps97. DOI: 10.1200/jco.2024.42.23_suppl.tps97.Peer-Reviewed Original ResearchDose-escalation partGastrointestinal stromal tumorsProgression-free survivalDays on/2 daysResistance to IMStromal tumorsImatinib-refractory gastrointestinal stromal tumorsInvestigator-assessed progression-free survivalAdvanced gastrointestinal stromal tumorsKinase-domain mutationsOvercome IM resistanceWeeks on/2 weeksDisease control rateDose-limiting toxicitySecond-line settingDuration of responseMaximum tolerated dosePhase I studyPhase 3 studyPhase 1 studySoft tissue sarcomasHsp90 inhibitorsInhibited tumor growthAnti-tumor activityOverall survivalThe role of 18F-FDG PET in minimizing variability in gross tumor volume delineation of soft tissue sarcomas
Najem E, Marin T, Zhuo Y, Lahoud R, Tian F, Beddok A, Rozenblum L, Xing F, Moteabbed M, Lim R, Liu X, Woo J, Lostetter S, Lamane A, Chen Y, Ma C, El Fakhri G. The role of 18F-FDG PET in minimizing variability in gross tumor volume delineation of soft tissue sarcomas. Radiotherapy And Oncology 2024, 194: 110186. PMID: 38412906, PMCID: PMC11042980, DOI: 10.1016/j.radonc.2024.110186.Peer-Reviewed Original ResearchGross tumor volume delineationGross tumor volumeDice similarity coefficientF-FDG PET imagingSoft tissue sarcomasInter-reader variabilityGTV delineationRadiation therapy treatment planningF-FDGF-FDG PETTherapy treatment planningPerformance level estimationTumor volume delineationTissue sarcomasPET imagingVolume delineationSimultaneous truthHausdorff distanceDice similarity coefficient scoreAccurate gross tumor volumeImaging modality groupsWilcoxon signed-rank testStatistically significant decreaseSigned-rank testTumor volumeClinical Outcomes Among Immunotherapy-Treated Patients With Primary Cardiac Soft Tissue Sarcomas A Multicenter Retrospective Study
Nassar A, El-Am E, Denu R, Alaiwi S, Zarif T, Macaron W, Abdel-Wahab N, Desai A, Smith C, Parikh K, Abbasi M, Farhat E, Williams J, Collins J, Al-Hader A, McKay R, Malvar C, Sabra M, Zhong C, Alam R, Chehab O, Lima J, Phan M, Pria H, Trevino A, Neilan T, Kwan J, Ravi V, Deshpande H, Demetri G, Choueiri T, Naqash A. Clinical Outcomes Among Immunotherapy-Treated Patients With Primary Cardiac Soft Tissue Sarcomas A Multicenter Retrospective Study. JACC CardioOncology 2024, 6: 71-79. PMID: 38510282, PMCID: PMC10950431, DOI: 10.1016/j.jaccao.2023.11.007.Peer-Reviewed Original ResearchMedian progression-free survivalProgression-free survivalImmune checkpoint inhibitorsSoft tissue sarcomasOverall survivalMedian OSTissue sarcomasClinical outcomesCommon Terminology Criteria for Adverse Events versionTreatment-related adverse eventsClinical outcomes of patientsMulti-institutional cohort studyResponse rateICI-based regimensObjective response rateSolid Tumors versionAdverse Events versionLocally advanced diseaseResponse Evaluation CriteriaImmunotherapy-treated patientsSecond-line therapyEstimate overall survivalFirst-line therapyMulticenter retrospective studyKaplan-Meier method
2023
Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomas
Kummar S, Shen L, Hong D, McDermott R, Keedy V, Casanova M, Demetri G, Dowlati A, Melcón S, Lassen U, Leyvraz S, Liu T, Moreno V, Patel J, Patil T, Mallick A, Sousa N, Tahara M, Ziegler D, Norenberg R, Arvis P, Brega N, Drilon A, Tan D. Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomas. Cancer 2023, 129: 3772-3782. PMID: 37769113, PMCID: PMC11265530, DOI: 10.1002/cncr.35036.Peer-Reviewed Original ResearchConceptsTropomyosin receptor kinaseNTRK gene fusionsAdult patientsFusion sarcomaAdverse eventsData cutoffGrade 3 treatment-emergent adverse eventsTropomyosin receptor kinase fusion cancerCohort of adult patientsClinical management of adult patientsExtended survival benefitSafety of larotrectinibManagement of adult patientsGastrointestinal stromal tumorsSoft tissue sarcomasTreatment of patientsFirst-in-classGene fusionsInvestigator-assessedNTRK genesReceptor kinaseStromal tumorsSurvival benefitPediatric patientsSolid tumorsAtezolizumab for Advanced Alveolar Soft Part Sarcoma
Chen A, Sharon E, O'Sullivan-Coyne G, Moore N, Foster J, Hu J, Van Tine B, Conley A, Read W, Riedel R, Burgess M, Glod J, Davis E, Merriam P, Naqash A, Fino K, Miller B, Wilsker D, Begum A, Ferry-Galow K, Deshpande H, Schwartz G, Ladle B, Okuno S, Beck J, Chen J, Takebe N, Fogli L, Rosenberger C, Parchment R, Doroshow J. Atezolizumab for Advanced Alveolar Soft Part Sarcoma. New England Journal Of Medicine 2023, 389: 911-921. PMID: 37672694, PMCID: PMC10729808, DOI: 10.1056/nejmoa2303383.Peer-Reviewed Original ResearchConceptsAdvanced alveolar soft part sarcomaAlveolar soft part sarcomaProgression-free survivalSoft part sarcomaObjective responsePart sarcomaMedian progression-free survivalTreatment-related grade 4Rare soft tissue sarcomaData cutoff dateImmune checkpoint inhibitorsPhase 2 studyResponse Evaluation CriteriaThird of patientsDuration of responseSoft tissue sarcomasYears of treatmentCheckpoint inhibitorsAdverse eventsMedian durationPartial responseComplete responseDeath-1PD-L1Pediatric patientsOutcomes After Preoperative Chemoradiation With or Without Pazopanib in Non-Rhabdomyosarcoma Soft Tissue Sarcoma: A Report From Children's Oncology Group and NRG Oncology
Weiss A, Chen Y, Scharschmidt T, Xue W, Gao Z, Black J, Choy E, Davis J, Fanburg-Smith J, Kao S, Kayton M, Kessel S, Lim R, Million L, Okuno S, Ostrenga A, Parisi M, Pryma D, Randall R, Rosen M, Shulkin B, Terezakis S, Venkatramani R, Zambrano E, Wang D, Hawkins D, Spunt S. Outcomes After Preoperative Chemoradiation With or Without Pazopanib in Non-Rhabdomyosarcoma Soft Tissue Sarcoma: A Report From Children's Oncology Group and NRG Oncology. Journal Of Clinical Oncology 2023, 41: 4842-4848. PMID: 37523624, PMCID: PMC10852395, DOI: 10.1200/jco.23.00045.Peer-Reviewed Original ResearchConceptsNon-rhabdomyosarcoma soft tissue sarcomasSoft tissue sarcomasRegimen BPreoperative chemoradiationRegimen ATissue sarcomasPathological responseMedian survivor follow-upComplete pathologic response ratePathological response rateEvent-free survivalPhase II studyPrimary end pointChildren's Oncology GroupIntent-to-treat analysisSurvivor follow-upNon-rhabdomyosarcomasPreoperative radiotherapyPrimary resectionOverall survivalOncology GroupII studyClinical trial updateNRG OncologyEligible patientsThe genomic landscape of adolescent and young adult (AYA) malignancies using DNA and RNA-based next generation sequencing.
Lustberg M, Kaneva K, Teslow E, Mauer E, Federman N, Eisfeld A. The genomic landscape of adolescent and young adult (AYA) malignancies using DNA and RNA-based next generation sequencing. Journal Of Clinical Oncology 2023, 41: e15091-e15091. DOI: 10.1200/jco.2023.41.16_suppl.e15091.Peer-Reviewed Original ResearchTriple-negative breast cancerTumor mutational burdenCancer patientsAYA patientsMicrosatellite instabilityBreast cancerNext-generation sequencingYoung adult cancer patientsYoung adult malignancyColorectal cancer patientsAdult cancer patientsHER2- breast cancerOlder adult patientsAYA cancer patientsSoft tissue sarcomasCentral nervous systemHigh-grade gliomasLow-grade gliomasPathogenic single nucleotide variantsAYA cancerSingle nucleotide variantsAdult patientsGastrointestinal malignanciesNTRK fusionsAML subgroups
2022
Feasibility study of clinical target volume definition for soft-tissue sarcoma using muscle fiber orientations derived from diffusion tensor imaging
Shusharina N, Liu X, Coll-Font J, Foster A, Fakhri G, Woo J, Bortfeld T, Nguyen C. Feasibility study of clinical target volume definition for soft-tissue sarcoma using muscle fiber orientations derived from diffusion tensor imaging. Physics In Medicine And Biology 2022, 67: 155013. PMID: 35817048, PMCID: PMC9344976, DOI: 10.1088/1361-6560/ac8045.Peer-Reviewed Original ResearchConceptsClinical target volumeSoft tissue sarcomasHealthy volunteersClinical target volume definitionClinical target volume delineationRight thighGross tumor volumeTarget volume definitionEcho-planar acquisitionsTarget volumeAuto-segmentationTumor volumeVolume definitionSarcoma patientsTissue sarcomasCT planeConvolutional neural networkT2-weightedCancer CenterPlanar acquisitionImaging sessionFat suppressionMR imagingSarcomaAnatomical orientationA phase Ia/Ib, dose-escalation/expansion study of BI 907828 in combination with BI 754091 (ezabenlimab) and BI 754111 in patients (pts) with advanced solid tumors.
Yamamoto N, Hafez N, Tolcher A, Teufel M, Geng J, Svensson L, Lahmar M, Gounder M. A phase Ia/Ib, dose-escalation/expansion study of BI 907828 in combination with BI 754091 (ezabenlimab) and BI 754111 in patients (pts) with advanced solid tumors. Journal Of Clinical Oncology 2022, 40: 3095-3095. DOI: 10.1200/jco.2022.40.16_suppl.3095.Peer-Reviewed Original ResearchDose-limiting toxicityImmune checkpoint inhibitorsDoublet combinationsCheckpoint inhibitorsPrimary endpointPhase Ia/Ib studySolid tumorsManageable safety profileMDM2-p53 antagonistsProgression-free survivalAdvanced solid tumorsBiliary tract carcinomaMetastatic solid tumorsSoft tissue sarcomasAnti-tumor effectsWild-type cancersAnti-tumor activityLogistic regression modelsPhase IaMultiple tumor typesG3 anemiaG3 neutropeniaG4 thrombocytopeniaIA/IBMurine double minute
2021
Deep learning-based GTV contouring modeling inter- and intra- observer variability in sarcomas
Marin T, Zhuo Y, Lahoud R, Tian F, Ma X, Xing F, Moteabbed M, Liu X, Grogg K, Shusharina N, Woo J, Lim R, Ma C, Chen Y, El Fakhri G. Deep learning-based GTV contouring modeling inter- and intra- observer variability in sarcomas. Radiotherapy And Oncology 2021, 167: 269-276. PMID: 34808228, PMCID: PMC8934266, DOI: 10.1016/j.radonc.2021.09.034.Peer-Reviewed Original ResearchConceptsGross tumor volumeRadiation therapy treatment planningGross tumor volume contoursGross tumor volume delineationTherapy treatment planningIntra-observer variabilityConsensus contoursGTV contoursPre-operative CT imagesSoft tissue sarcomasRadiation oncologistsTumor volumeBone sarcomasTreatment planningAccurate contoursCT imagesDelineation procedureSarcomaSoft tissueConfidence levelRadiationPatientsHausdorff distanceMultiple contoursX-rayEndometrial Carcinoma as the Presenting Malignancy in a Teenager With a Pathogenic TP53 Germline Mutation: A Case Report and Literature Review
Irshaid L, Clark M, Fadare O, Finberg KE, Parkash V. Endometrial Carcinoma as the Presenting Malignancy in a Teenager With a Pathogenic TP53 Germline Mutation: A Case Report and Literature Review. International Journal Of Gynecological Pathology 2021, 41: 258-267. PMID: 33990091, DOI: 10.1097/pgp.0000000000000792.Peer-Reviewed Original ResearchConceptsGermline TP53 mutationsEndometrial carcinomaTP53 mutationsGermline mutationsMissense substitution p.Predominant tumor typePremenopausal breast carcinomaAdrenal cortical tumorsTP53 geneTP53 germline mutationsSoft tissue sarcomasEndometrioid endometrial carcinomaEarly-onset malignanciesLi-Fraumeni syndromeAutosomal dominant disorderCortical tumorsPresenting tumourGynecologic malignanciesTissue sarcomasUterine carcinomaCase reportSpinal cordBreast carcinomaGrade 3Characteristic syndromeComparative Outcomes Between Osteosarcoma and Pediatric Soft Tissue Sarcomas Of Bone: A National Cancer Database Analysis
Yu K, Cahill S, Toombs C, Lindskog D. Comparative Outcomes Between Osteosarcoma and Pediatric Soft Tissue Sarcomas Of Bone: A National Cancer Database Analysis. Pediatrics 2021, 147: 784-786. DOI: 10.1542/peds.147.3ma8.784.Peer-Reviewed Original ResearchComparative Outcomes Between Osteosarcoma and Pediatric Soft Tissue Sarcomas Of Bone: A National Cancer Database Analysis
Yu K, Cahill S, Toombs C, Lindskog D. Comparative Outcomes Between Osteosarcoma and Pediatric Soft Tissue Sarcomas Of Bone: A National Cancer Database Analysis. 2021, 784-786. DOI: 10.1542/peds.147.3_meetingabstract.784.Peer-Reviewed Original ResearchEvaluation of head and neck soft tissue sarcoma 8th edition pathologic staging system and proposal of a novel stage grouping system
Lee NCJ, Eskander A, Miccio JA, Park HS, Shah C, Rutenberg M, Hosni A, Husain ZA. Evaluation of head and neck soft tissue sarcoma 8th edition pathologic staging system and proposal of a novel stage grouping system. Oral Oncology 2021, 114: 105137. PMID: 33422859, DOI: 10.1016/j.oraloncology.2020.105137.Peer-Reviewed Original ResearchConceptsNeck soft tissue sarcomasTumor size cutNational Cancer DatabaseSoft tissue sarcomasMultivariable analysisTissue sarcomasFive-year overall survivalNeoadjuvant therapy patientsT1-3 tumorsEnd Results (SEER) databaseAdjacent structuresEvaluation of headPaucity of dataNCDB cohortSEER cohortPrimary surgeryOverall survivalWorsened survivalAdverse prognosticatorPrognostic differencesResults databaseStaging systemT4 classificationTumor stageCancer DatabaseGenetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
Daly M, Pal T, Berry M, Buys S, Dickson P, Domchek S, Elkhanany A, Friedman S, Goggins M, Hutton M, Karlan B, Khan S, Klein C, Kohlmann W, Kurian A, Laronga C, Litton J, Mak J, Menendez C, Merajver S, Norquist B, Offit K, Pederson H, Reiser G, Senter-Jamieson L, Shannon K, Shatsky R, Visvanathan K, Weitzel J, Wick M, Wisinski K, Yurgelun M, Darlow S, Dwyer M. Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2021, 19: 77-102. PMID: 33406487, DOI: 10.6004/jnccn.2021.0001.Peer-Reviewed Original ResearchConceptsLikely pathogenic variantsLi-Fraumeni syndromePathogenic variantsPancreatic cancerGenetic/Familial High-Risk AssessmentCancer syndromesNCCN Clinical Practice GuidelinesBreast/ovarian cancer syndromePremenopausal breast cancerClinical practice guidelinesSoft tissue sarcomasHigh lifetime riskOvarian cancer syndromeGenetic testing/counselingRisk of breastPenetrant cancer syndromeNCCN guidelinesTissue sarcomasAdrenocortical carcinomaLifetime riskOvarian cancerProstate cancerBreast cancerGastric cancerHigh-risk assessment
2020
The Impact of Obesity on Tumor Glucose Uptake in Breast and Lung Cancer
Leitner BP, Perry RJ. The Impact of Obesity on Tumor Glucose Uptake in Breast and Lung Cancer. JNCI Cancer Spectrum 2020, 4: pkaa007. PMID: 32368718, PMCID: PMC7190208, DOI: 10.1093/jncics/pkaa007.Peer-Reviewed Original ResearchBody mass indexTumor glucose uptakeLung cancerGlucose uptakeGlucose metabolismNon-small cell lung cancerHigher body mass indexObesity-cancer linkImpact of obesityCell lung cancerSquamous cell carcinomaSoft tissue sarcomasAltered glucose metabolismPoor clinical prognosisTumor glucose metabolismMass indexPoor outcomeTissue sarcomasCell carcinomaTomography/Clinical prognosisBreast cancerProtective effectObesityCancerA Phase 1b Study Evaluating the Safety, Tolerability, and Immunogenicity of CMB305, a Lentiviral-Based Prime-Boost Vaccine Regimen, in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1
Somaiah N, Chawla SP, Block MS, Morris JC, Do K, Kim JW, Druta M, Sankhala KK, Hwu P, Jones RL, Gnjatic S, Kim-Schulze S, Tuballes K, Yishak M, Lu H, Yakovich A, Meulen J, Chen M, Kenney RT, Bohac C, Pollack SM. A Phase 1b Study Evaluating the Safety, Tolerability, and Immunogenicity of CMB305, a Lentiviral-Based Prime-Boost Vaccine Regimen, in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1. OncoImmunology 2020, 9: 1847846. PMID: 33312760, PMCID: PMC7714520, DOI: 10.1080/2162402x.2020.1847846.Peer-Reviewed Original ResearchConceptsNY-ESO-1Prime-boost vaccine regimenVaccine regimenImmune responseNY-ESO-1 immune responsesNY-ESO-1 antibodyNY-ESO-1 proteinToll-like receptor agonistsInjection site painOral metronomic cyclophosphamidePhase 1b studyRecombinant protein boostCommon adverse eventsDisease control ratePrime-boost vaccineT cell responsesDose-escalation designSoft tissue sarcomasLentiviral vectorsMetronomic cyclophosphamideAdverse eventsMetastatic diseaseOverall survivalProgressive diseaseStudy entry
2019
Predictors of Lymph Node Involvement by Soft Tissue Sarcoma of the Trunk and Extremity: An Analysis of the National Cancer Database
Miccio JA, Jairam V, Gao S, Augustyn A, Oladeru OT, Onderdonk BE, Chowdhary M, Han D, Khan S, Friedlaender G, Lindskog DM, Desphande HA, Osborn H, Roberts KB, Patel KR. Predictors of Lymph Node Involvement by Soft Tissue Sarcoma of the Trunk and Extremity: An Analysis of the National Cancer Database. Cureus 2019, 11: e6038. PMID: 31824805, PMCID: PMC6886621, DOI: 10.7759/cureus.6038.Peer-Reviewed Original ResearchSoft tissue sarcomasPathologic nodal evaluationNational Cancer DatabaseLymphovascular invasionNodal evaluationRisk factorsMultivariable logistic regression modelExtremity STS patientsGrade 3 tumorsHigh-risk groupTrunk/extremitiesLogistic regression modelsNeoadjuvant therapyWorse survivalRetrospective reviewSTS patientsDistant metastasisMultivariable analysisEpithelioid histologyTissue sarcomasCancer DatabaseExclusion criteriaPatientsLNMMetastasis
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply